OBJECTIVE: To explore the expression of MMP2 and its correlation with the clinical features and prognosis of endometrial adenocarcinoma. METHODS: We collected paraffin-embedded samples from 81 patients with endometrial adenocarcinoma aged 32 to 80 years to examine the expression of MMP2 using immunohistochemistry. The correlation of MMP2 expression with the clinical characteristics and prognosis of the patients was analyzed. RESULTS: MMP2 protein was expressed in the cytoplasm of the tumor cells. MMP2 over-expression was negatively correlated with tumor differentiation (P=0.015) and prognosis (P=0.041) of endometrial adenocarcinoma. CONCLUSION: MMP2 over-expression is a potential malignant biomarker in endometrial adenocarcinoma.
OBJECTIVE: To explore the expression of MMP2 and its correlation with the clinical features and prognosis of endometrial adenocarcinoma. METHODS: We collected paraffin-embedded samples from 81 patients with endometrial adenocarcinoma aged 32 to 80 years to examine the expression of MMP2 using immunohistochemistry. The correlation of MMP2 expression with the clinical characteristics and prognosis of the patients was analyzed. RESULTS:MMP2 protein was expressed in the cytoplasm of the tumor cells. MMP2 over-expression was negatively correlated with tumor differentiation (P=0.015) and prognosis (P=0.041) of endometrial adenocarcinoma. CONCLUSION:MMP2 over-expression is a potential malignant biomarker in endometrial adenocarcinoma.